Cargando…

Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study

BACKGROUND: The increasing rate of drug resistance often leads to Helicobacter pylori (H. pylori) eradication failure and needs the rescue therapy. Thus, the exploration of new rescue therapeutic regimens is important. The present study was designed to test the beneficial effects of Saccharomyces bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Peng, Liu, Xiaoming, Xia, Xiujuan, Xie, Xiaoran, Luo, Ju, Cheng, Sha, Chi, Jingshu, Liu, Peng, Li, Huan, Zhao, Wenfang, Yang, Huihao, Xu, Canxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307992/ https://www.ncbi.nlm.nih.gov/pubmed/35880079 http://dx.doi.org/10.3389/fcimb.2022.903002

Ejemplares similares

Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study
por: Cheng, Sha, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial
por: Zhao, Yuchong, et al.
Publicado: (2021)

Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
por: Yoon, Jai Hoon, et al.
Publicado: (2012)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China
por: Chi, Jingshu, et al.
Publicado: (2022)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
por: Namkin, Kokab, et al.
Publicado: (2016)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
por: Wang, Junxian, et al.
Publicado: (2021)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Corrigendum to “Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori”
por: Zhang, Lingyun, et al.
Publicado: (2021)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

The effects of Saccharomyces boulardii on rat colonic hypermotility induced by repeated water avoidance stress and the potential mechanism
por: Liu, Jingwen, et al.
Publicado: (2022)

Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
por: Sulik-Tyszka, Beata, et al.
Publicado: (2017)

Biocontainment strategies for in vivo applications of Saccharomyces boulardii
por: Hedin, Karl Alex, et al.
Publicado: (2023)

Rescue and Reuse
por: Morrison, Ian, et al.
Publicado: (2019)

The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children
por: Bin, Zhang, et al.
Publicado: (2015)

Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial
por: Naghibzadeh, Nooshin, et al.
Publicado: (2022)

Exosomal CagA from Helicobacter pylori aggravates intestinal epithelium barrier dysfunction in chronic colitis by facilitating Claudin-2 expression
por: Guo, Yinjie, et al.
Publicado: (2022)

Saccharomyces boulardii: What Makes It Tick as Successful Probiotic?
por: Pais, Pedro, et al.
Publicado: (2020)

Helicobacter Pylori Induces GATA3-Dependent Chitinase 3 Like 1 (CHI3L1) Upregulation and Contributes to Vascular Endothelial Injuries
por: Chi, Jingshu, et al.
Publicado: (2019)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Empiric “Three-in-One” Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy
por: Losurdo, Giuseppe, et al.
Publicado: (2022)

European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice
por: Nyssen, Olga P., et al.
Publicado: (2021)

The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after Helicobacter pylori Eradication: A Randomized Controlled Trial
por: Wu, Dingkun, et al.
Publicado: (2022)

Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
por: Kazemi Veysari, Arash, et al.
Publicado: (2023)

FTO-mediated m(6)A modification promotes malignant transformation of gastric mucosal epithelial cells in chronic Cag A(+) Helicobacter pylori infection
por: Cheng, Sha, et al.
Publicado: (2023)

An unexpected allergic reaction with Saccharomyces boulardii: a case report
por: Kartal, Ozgur, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_argbp3l19vhv0g8hdrndbd91b5